<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03129451</url>
  </required_header>
  <id_info>
    <org_study_id>Parkinson's Microbiome</org_study_id>
    <nct_id>NCT03129451</nct_id>
  </id_info>
  <brief_title>The Microbiome in Parkinson's Disease</brief_title>
  <official_title>The Microbiome in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Health Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Van Andel Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spectrum Health Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the dynamic relationship between the intestinal microbiota and Inflammation in&#xD;
      subjects with Parkinson's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the dynamic relationship between the intestinal microbiota and Inflammation in&#xD;
      subjects with Parkinson's disease. The current study examines the differential microbiome of&#xD;
      the gut in subjects with parkinsonism. The current study determines whether certain&#xD;
      Parkinson's subtypes are prone to pro-inflammatory microbiomes. This study also explores&#xD;
      whether the intestinal microbiome in post-appendectomy Parkinson's subjects is modified as&#xD;
      appendix has a role in regulating intestinal microbiome. The current study will examine&#xD;
      whether microbiome changes influence inflammatory markers in the blood.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 17, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The current study determines whether certain Parkinson's subtypes are prone to pro-inflammatory microbiomes.</measure>
    <time_frame>3 years</time_frame>
    <description>Differences in microbiome abundance will be detected using a Kruskal-Wallis' test generating a Benjamini-Hochberg false discovery rate (FDR)-corrected P value (&lt;0.05 for significance). For the microbiome analysis, in silico community functional predictions will be performed using PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) and significant differences in Kyoto Encyclopedia of Genes and Genomes (KEGG) ortholog (KO) abundances between groups will be identified (FDR-corrected P value &lt;0.05 for significance). Putative &quot;proinflammatory&quot; and &quot;anti-inflammatory&quot; bacteria taxa will be classified based on previous reports (and the references therein) (see Keshavarzian et al., 2015). Differences in inflammatory metabolite abundance will be detected using a Kruskal-Wallis' test generating a Benjamini-Hochberg false discovery rate (FDR)-corrected P value (0.05).</description>
  </primary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Tremor-dominant</arm_group_label>
    <description>Tremor-dominant Parkinson's disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Akinetic-Rigid</arm_group_label>
    <description>Akinetic-Rigid type Parkinson's disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple systems atrophy</arm_group_label>
    <description>Multiple systems atrophy PD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levodopa-naïve</arm_group_label>
    <description>Levodopa-naïve Parkinson's disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tremor-dominant / app</arm_group_label>
    <description>Tremor-dominant Parkinson's disease with an appendectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Akinetic-Rigid / app</arm_group_label>
    <description>Akinetic-Rigid Parkinson's disease with an appendectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levodopa-naïve w/app</arm_group_label>
    <description>Levodopa-naïve Parkinson's disease with an appendectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Microbiome specimens in stool</intervention_name>
    <description>Analyzing Microbiome specimens in stool</description>
    <arm_group_label>Akinetic-Rigid</arm_group_label>
    <arm_group_label>Akinetic-Rigid / app</arm_group_label>
    <arm_group_label>Levodopa-naïve</arm_group_label>
    <arm_group_label>Levodopa-naïve w/app</arm_group_label>
    <arm_group_label>Multiple systems atrophy</arm_group_label>
    <arm_group_label>Tremor-dominant</arm_group_label>
    <arm_group_label>Tremor-dominant / app</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        We will examine individuals with 1) Tremor-dominant Parkinson's disease, 2) Akinetic-Rigid&#xD;
        type Parkinson's disease, 3) Multiple systems atrophy (MSA-P), 4) Levodopa-naïve&#xD;
        Parkinson's disease, 5) Tremor-dominant Parkinson's disease with an appendectomy, 6)&#xD;
        Akinetic-Rigid Parkinson's disease with an appendectomy, 7) Levodopa-naïve Parkinson's&#xD;
        disease with an appendectomy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals with Parkinson's disease (including multiple system atrophy). Males and&#xD;
             females are eligible for the study. Appendectomized cohort must have had their&#xD;
             appendectomy at least 20 years before Parkinson's disease onset&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Body Mass Index greater than or equal to 35 or less than or equal to 18. 2. Vital&#xD;
             signs outside of acceptable range at Screening Visit, i.e., blood pressure &gt;160/100,&#xD;
             oral temperature &gt;100°F, pulse &gt;100.&#xD;
&#xD;
             3. Use of any of the following drugs within the last 6 months:&#xD;
&#xD;
               -  systemic antibiotics, antifungals, antivirals or antiparasitics (intravenous,&#xD;
                  intramuscular, or oral);&#xD;
&#xD;
               -  cytokines;&#xD;
&#xD;
               -  methotrexate or immunosuppressive cytotoxic agents;&#xD;
&#xD;
               -  large doses of commercial probiotics consumed (greater than or equal to 108 cfu&#xD;
                  or organisms per day) - includes tablets, capsules, lozenges, chewing gum or&#xD;
                  powders in which probiotic is a primary component. Ordinary dietary components&#xD;
                  such as fermented beverages/milks, yogurts, foods do not apply.&#xD;
&#xD;
                  4. Acute viral/bacterial infection disease at the time of sampling (defer&#xD;
                  sampling until subject recovers). Acute disease is defined as the presence of a&#xD;
                  moderate or severe illness with or without fever.&#xD;
&#xD;
                  5. Unstable dietary history as defined by major changes in diet during the&#xD;
                  previous month, where the subject has eliminated or significantly increased a&#xD;
                  major food group in the diet.&#xD;
&#xD;
                  6. Recent history of chronic alcohol consumption defined as more than five 1.5-&#xD;
                  ounce servings of 80 proof distilled spirits, five 12-ounce servings of beer or&#xD;
                  five 5-ounce servings of wine per day.&#xD;
&#xD;
                  7. Positive test for HIV, HBV or HCV. 8. Any confirmed or suspected&#xD;
                  condition/state of immunosuppression or immunodeficiency (primary or acquired)&#xD;
                  including HIV infection.&#xD;
&#xD;
                  9. Major surgery of the GI tract, with the exception of cholecystectomy and&#xD;
                  appendectomy, in the past five years. Any major bowel resection at any time.&#xD;
&#xD;
                  10. History of active uncontrolled gastrointestinal disorders or diseases&#xD;
                  including:&#xD;
&#xD;
               -  inflammatory bowel disease (IBD) including ulcerative colitis&#xD;
                  (mild-moderate-severe), Crohn's disease (mild-moderate-severe), or indeterminate&#xD;
                  colitis;&#xD;
&#xD;
               -  irritable bowel syndrome (IBS) (moderate-severe);&#xD;
&#xD;
               -  persistent, infectious gastroenteritis, colitis or gastritis, persistent or&#xD;
                  chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent)&#xD;
                  or Helicobacter pylori infection (untreated); 11. Female who is pregnant or&#xD;
                  lactating. 12. Atypical or secondary Parkinson's disease 13. Adults that are&#xD;
                  unable to consent, individuals that are not yet adults and prisoners are not&#xD;
                  eligible for this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ashok Sriram</last_name>
    <phone>616-267-7900</phone>
    <email>ashok.sriram@spectrumhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Casey Doyle</last_name>
    <phone>616-486-6128</phone>
    <email>casey.doyle@spectrumhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casey Doyle</last_name>
      <phone>616-486-6128</phone>
      <email>casey.doyle@spectrumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Ashok Sriram</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>April 19, 2017</study_first_submitted>
  <study_first_submitted_qc>April 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>April 21, 2017</last_update_submitted>
  <last_update_submitted_qc>April 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Spectrum Health Hospitals</investigator_affiliation>
    <investigator_full_name>Casey Michael Doyle</investigator_full_name>
    <investigator_title>CRC</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

